- Home
- DEA vs NRIX Comparison
DEA vs NRIX Comparison
Compare DEA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- NRIX
- Stock Information
- Founded
- DEA 2011
- NRIX 2009
- Country
- DEA United States
- NRIX United States
- Employees
- DEA N/A
- NRIX N/A
- Industry
- DEA Real Estate Investment Trusts
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- NRIX Health Care
- Exchange
- DEA Nasdaq
- NRIX Nasdaq
- Market Cap
- DEA 912.0M
- NRIX 1.1B
- IPO Year
- DEA 2015
- NRIX 2020
- Fundamental
- Price
- DEA $20.74
- NRIX $9.58
- Analyst Decision
- DEA Hold
- NRIX Strong Buy
- Analyst Count
- DEA 4
- NRIX 17
- Target Price
- DEA $29.06
- NRIX $30.71
- AVG Volume (30 Days)
- DEA 721.7K
- NRIX 895.9K
- Earning Date
- DEA 04-29-2025
- NRIX 07-10-2025
- Dividend Yield
- DEA 6.01%
- NRIX N/A
- EPS Growth
- DEA N/A
- NRIX N/A
- EPS
- DEA 0.41
- NRIX N/A
- Revenue
- DEA $314,385,000.00
- NRIX $56,417,000.00
- Revenue This Year
- DEA $7.23
- NRIX $15.43
- Revenue Next Year
- DEA $7.93
- NRIX N/A
- P/E Ratio
- DEA $50.82
- NRIX N/A
- Revenue Growth
- DEA 6.82
- NRIX N/A
- 52 Week Low
- DEA $19.33
- NRIX $8.18
- 52 Week High
- DEA $36.31
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- DEA 43.21
- NRIX 38.72
- Support Level
- DEA $20.53
- NRIX $9.02
- Resistance Level
- DEA $21.09
- NRIX $10.38
- Average True Range (ATR)
- DEA 0.64
- NRIX 0.57
- MACD
- DEA 0.26
- NRIX -0.04
- Stochastic Oscillator
- DEA 70.49
- NRIX 20.66
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.